• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

高密度脂蛋白通过激活清道夫受体BI刺激细胞进入,从而抑制丙型肝炎病毒中和抗体。

High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI.

作者信息

Dreux Marlène, Pietschmann Thomas, Granier Christelle, Voisset Cécile, Ricard-Blum Sylvie, Mangeot Philippe-Emmanuel, Keck Zhenyong, Foung Steven, Vu-Dac Ngoc, Dubuisson Jean, Bartenschlager Ralf, Lavillette Dimitri, Cosset Francois-Loïc

机构信息

INSERM, U758, 69007 Lyon, France.

出版信息

J Biol Chem. 2006 Jul 7;281(27):18285-95. doi: 10.1074/jbc.M602706200. Epub 2006 May 4.

DOI:10.1074/jbc.M602706200
PMID:16675450
Abstract

Hepatitis C virus (HCV) exploits serum-dependent mechanisms that inhibit neutralizing antibodies. Here we demonstrate that high density lipoprotein (HDL) is a key serum factor that attenuates neutralization by monoclonal and HCV patient-derived polyclonal antibodies of infectious pseudo-particles (HCVpp) harboring authentic E1E2 glycoproteins and cell culture-grown genuine HCV (HCVcc). Over 10-fold higher antibody concentrations are required to neutralize either HCV-enveloped particles in the presence of HDL or human serum, and less than 3-5-fold reduction of infectious titers are obtained at saturating antibody concentrations, in contrast to complete inhibition in serum-free conditions. We show that HDL interaction with the scavenger receptor BI (SR-BI), a proposed cell entry co-factor of HCV and a receptor mediating lipid transfer with HDL, strongly reduces neutralization of HCVpp and HCVcc. We found that HDL activation of target cells strongly stimulates cell entry of viral particles by accelerating their endocytosis, thereby suppressing a 1-h time lag during which cell-bound virions are not internalized and can be targeted by antibodies. Compounds that inhibit lipid transfer functions of SR-BI fully restore neutralization by antibodies in human serum. We demonstrate that this functional HDL/SR-BI interaction only interferes with antibodies blocking HCV-E2 binding to CD81, a major HCV receptor, reflecting its prominent role during the cell entry process. Moreover, we identify monoclonal antibodies targeted to epitopes in the E1E2 complex that are not inhibited by HDL. Consistently, we show that antibodies targeted to HCV-E1 efficiently neutralize HCVpp and HCVcc in the presence of human serum.

摘要

丙型肝炎病毒(HCV)利用血清依赖性机制来抑制中和抗体。在此,我们证明高密度脂蛋白(HDL)是一种关键的血清因子,它能减弱单克隆抗体以及HCV患者来源的多克隆抗体对携带真实E1E2糖蛋白的感染性假病毒颗粒(HCVpp)和细胞培养产生的真正HCV(HCVcc)的中和作用。在HDL或人血清存在的情况下,中和HCV包膜颗粒需要的抗体浓度要高出10倍以上,并且在饱和抗体浓度下,感染滴度降低不到3 - 5倍,而在无血清条件下则完全抑制。我们表明,HDL与清道夫受体BI(SR - BI)相互作用,SR - BI是一种推测的HCV细胞进入辅助因子,也是介导HDL脂质转运的受体,这会强烈降低HCVpp和HCVcc的中和作用。我们发现HDL激活靶细胞可通过加速其胞吞作用来强烈刺激病毒颗粒的细胞进入,从而消除1小时的时间延迟,在此期间细胞结合的病毒粒子不会被内化,因而可被抗体靶向。抑制SR - BI脂质转运功能的化合物能完全恢复人血清中抗体的中和作用。我们证明这种功能性HDL/SR - BI相互作用仅干扰抗体阻断HCV - E2与主要HCV受体CD81的结合,这反映了其在细胞进入过程中的重要作用。此外,我们鉴定出针对E1E2复合物中HDL不抑制的表位的单克隆抗体。一致地,我们表明针对HCV - E1的抗体在人血清存在的情况下能有效中和HCVpp和HCVcc。

相似文献

1
High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI.高密度脂蛋白通过激活清道夫受体BI刺激细胞进入,从而抑制丙型肝炎病毒中和抗体。
J Biol Chem. 2006 Jul 7;281(27):18285-95. doi: 10.1074/jbc.M602706200. Epub 2006 May 4.
2
Neutralizing host responses in hepatitis C virus infection target viral entry at postbinding steps and membrane fusion.在丙型肝炎病毒感染中,中和宿主反应在结合后步骤和膜融合时靶向病毒进入。
Gastroenterology. 2008 Nov;135(5):1719-1728.e1. doi: 10.1053/j.gastro.2008.07.018. Epub 2008 Jul 22.
3
High-avidity monoclonal antibodies against the human scavenger class B type I receptor efficiently block hepatitis C virus infection in the presence of high-density lipoprotein.针对人类清道夫B类I型受体的高亲和力单克隆抗体在高密度脂蛋白存在的情况下能有效阻断丙型肝炎病毒感染。
J Virol. 2007 Aug;81(15):8063-71. doi: 10.1128/JVI.00193-07. Epub 2007 May 16.
4
High-density lipoproteins reduce the neutralizing effect of hepatitis C virus (HCV)-infected patient antibodies by promoting HCV entry.高密度脂蛋白通过促进丙型肝炎病毒(HCV)进入,降低HCV感染患者抗体的中和作用。
J Gen Virol. 2006 Sep;87(Pt 9):2577-2581. doi: 10.1099/vir.0.81932-0.
5
Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81.I型清道夫受体B类分子是丙型肝炎病毒感染的关键宿主因子,是与CD81密切相关的病毒进入步骤所必需的。
Hepatology. 2007 Dec;46(6):1722-31. doi: 10.1002/hep.21994.
6
Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity.丙型肝炎病毒E2中位于CD81结合位点之外的突变会导致病毒逃脱广泛中和抗体的作用,但会损害病毒的感染性。
J Virol. 2009 Jun;83(12):6149-60. doi: 10.1128/JVI.00248-09. Epub 2009 Mar 25.
7
High density lipoproteins facilitate hepatitis C virus entry through the scavenger receptor class B type I.高密度脂蛋白通过I型B类清道夫受体促进丙型肝炎病毒进入。
J Biol Chem. 2005 Mar 4;280(9):7793-9. doi: 10.1074/jbc.M411600200. Epub 2005 Jan 4.
8
Role of scavenger receptor class B type I in hepatitis C virus entry: kinetics and molecular determinants.清道夫受体 B 类 I 型在丙型肝炎病毒进入中的作用:动力学和分子决定因素。
J Virol. 2010 Jan;84(1):34-43. doi: 10.1128/JVI.02199-08.
9
A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1.一种重组丙型肝炎病毒 1a 型 E1/E2 包膜糖蛋白疫苗可诱导产生抗体,通过 E2 的 N 端高变区 1 与清道夫受体 B1 的相互作用,使这些抗体对密切相关的 2a 株产生不同的中和作用。
J Virol. 2019 Oct 29;93(22). doi: 10.1128/JVI.00810-19. Print 2019 Nov 15.
10
Receptor complementation and mutagenesis reveal SR-BI as an essential HCV entry factor and functionally imply its intra- and extra-cellular domains.受体互补和诱变研究表明,SR-BI是丙型肝炎病毒(HCV)进入细胞所必需的因子,并在功能上暗示了其细胞内和细胞外结构域的作用。
PLoS Pathog. 2009 Feb;5(2):e1000310. doi: 10.1371/journal.ppat.1000310. Epub 2009 Feb 20.

引用本文的文献

1
Lipoprotein receptors: A little grease for enveloped viruses to open the lock?脂蛋白受体:包膜病毒开启“锁具”的一点“润滑剂”?
J Biol Chem. 2024 Nov;300(11):107849. doi: 10.1016/j.jbc.2024.107849. Epub 2024 Sep 30.
2
Hepatitis C virus E1 recruits high-density lipoprotein to support infectivity and evade antibody recognition.丙型肝炎病毒 E1 招募高密度脂蛋白以支持感染性并逃避抗体识别。
J Virol. 2024 Jan 23;98(1):e0084923. doi: 10.1128/jvi.00849-23. Epub 2024 Jan 4.
3
In the era of rapid mRNA-based vaccines: Why is there no effective hepatitis C virus vaccine yet?
在基于信使核糖核酸的快速疫苗时代:为什么尚无有效的丙型肝炎病毒疫苗?
World J Hepatol. 2021 Oct 27;13(10):1234-1268. doi: 10.4254/wjh.v13.i10.1234.
4
Good Cholesterol Gone Bad? HDL and COVID-19.好胆固醇也能变坏事?HDL 与 COVID-19。
Int J Mol Sci. 2021 Sep 22;22(19):10182. doi: 10.3390/ijms221910182.
5
From Structural Studies to HCV Vaccine Design.从结构研究到丙型肝炎病毒疫苗设计。
Viruses. 2021 May 4;13(5):833. doi: 10.3390/v13050833.
6
HCV Glycoprotein Structure and Implications for B-Cell Vaccine Development.丙型肝炎病毒糖蛋白结构及其对 B 细胞疫苗开发的影响。
Int J Mol Sci. 2020 Sep 16;21(18):6781. doi: 10.3390/ijms21186781.
7
Hepatitis C virus vaccine design: focus on the humoral immune response.丙型肝炎病毒疫苗设计:关注体液免疫应答。
J Biomed Sci. 2020 Jul 6;27(1):78. doi: 10.1186/s12929-020-00669-4.
8
The ATGL lipase cooperates with ABHD5 to mobilize lipids for hepatitis C virus assembly.脂肪甘油三酯脂肪酶与 ABHD5 合作动员脂质用于丙型肝炎病毒组装。
PLoS Pathog. 2020 Jun 15;16(6):e1008554. doi: 10.1371/journal.ppat.1008554. eCollection 2020 Jun.
9
HCV Interplay with Lipoproteins: Inside or Outside the Cells?HCV 与脂蛋白的相互作用:在细胞内还是细胞外?
Viruses. 2020 Apr 12;12(4):434. doi: 10.3390/v12040434.
10
Hepatitis C Virus Vaccine: Challenges and Prospects.丙型肝炎病毒疫苗:挑战与前景
Vaccines (Basel). 2020 Feb 17;8(1):90. doi: 10.3390/vaccines8010090.